Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomised, Placebo-Controlled, Dietary Intervention Study

NCT07093346 is registered in ClinicalTrials.gov with University of Nottingham as lead sponsor.

NCT NCT07093346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07093346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomised, Placebo-Controlled, Dietary Intervention Study
Lead sponsor
University of Nottingham
Phase
Not applicable
Overall status
Recruiting
Start date
June 10, 2025
Completion date
March 31, 2027
Enrollment
45 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

masld, masld - metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatotic liver disease, nafld, nafld (non-alcoholic fatty liver disease), nafld (nonalcoholic fatty liver disease), nafld - non-alcoholic fatty liver disease, nafld - nonalcoholic fatty liver disease, nonalcoholic fatty liver disease, nonalcoholic fatty liver disease (nafld)